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Abstract
Background: The pathogenesis of nasopharyngeal carcinoma (NPC) is a complicated process
involving genetic predisposition, Epstein-Bar Virus infection, and genetic alterations. Although some
oncogenes and tumor suppressor genes have been previously reported in NPC, a complete
understanding of the pathogenesis of NPC in the context of global gene expression, transcriptional
pathways and biomarker assessment remains to be elucidated.
Methods: Total RNA from 32 pathologically-confirmed cases of poorly-differentiated NPC was
divided into pools inclusive of four consecutive specimens and each pool (T1 to T8) was co-
hybridized with pooled RNA from 24 normal non-cancerous nasopharyngeal tissues (NP) to a
human 8K cDNA array platform. The reliability of microarray data was validated for selected genes
by semi-quantitative RT-PCR and immunohistochemistry.
Results: Stringent statistical filtering parameters identified 435 genes to be up-regulated and 257
genes to be down-regulated in NPC compared to NP. Seven up-regulated genes including CYC1,
MIF, LAMB3, TUBB2, UBE2C and TRAP1 had been previously proposed as candidate common
cancer biomarkers based on a previous extensive comparison among various cancers and normal
tissues which did not, however, include NPC or NP. In addition, nine known oncogenes and tumor
suppressor genes, MIF, BIRC5, PTTG1, ATM, FOXO1A, TGFBR2, PRKAR1A, KLF5 and PDCD4
were identified through the microarray literature-based annotation search engine MILANO,
suggesting these genes may be specifically involved in the promotion of the malignant conversion
of nasopharyngeal epithelium. Finally, we found that these differentially expressed genes were
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involved in apoptosis, MAPK, VEGF and B cell receptor signaling pathways and other functions
associated with cell growth, signal transduction and immune system activation.
Conclusion: This study identified potential candidate biomarkers, oncogenes/tumor suppressor
genes involved in several pathways relevant to the oncogenesis of NPC. This information may
facilitate the determination of diagnostic and therapeutic targets for NPC as well as provide insights
about the molecular pathogenesis of NPC.
Background
The synergetic effect of virus infection, genetic aberrations
and environmental factors may lead to sequential altera-
tions of gene expression involved in several biological
pathways at different stages of nasopharyngeal carcinoma
(NPC) oncogenesis. Contemporary advances in cancer
genomic analysis including microarray, array-based high
throughput comparative genomic hybridization (aCGH),
detection of promoter hypermethylation, and analysis of
gene mutation have greatly accelerated our understanding
of NPC-associated genes. With the increased application
of microarray technology to investigate genes differen-
tially expressed in NPC[1,2], many functional associa-
tions with NPC pathogenesis have been gradually
discovered[3,4]. Accumulation of CGH data indicated
that genetic imbalances occur consistently in particular
chromosomal regions in which a high frequency of onco-
genes and tumor suppressor genes are gathered [3-8].
However, in spite of these important insights the patho-
genesis of NPC remains elusive as a complete identifica-
tion of genes associated with its development is not
available. Highly frequent mutations of p53 gene, a clas-
sical tumor suppressor gene, associated with most of
human malignancies, do not link to the pathogenesis of
sporadic NPC consistently, strongly suggesting NPC has
its specific pattern of gene expression and other genes may
play more significant roles in its oncogenesis and tumor
progression [9]. Therefore, in the present study, we uti-
lized 8K cDNA microarray and several bioinformatics
tools (KEGG database, online MILANO, BRB arraytool's
gene set comparison) to profile differential gene expres-
sion between NPC and NP samples from Southern China,
the region with highest NPC prevalence in the world. Sev-
eral oncogenes and tumor suppressor genes were identi-
fied as candidate biomarkers associated with important
pathways relevant to NPC oncogenesis, this may facilitate
the development of important diagnostic and therapeutic
targets for NPC as well as provide further insights about
the molecular pathogenesis of NPC.
Methods
Samples collection and screening
One-hundred-and-two primary tumor biopsies diagnosed
as poorly differentiated squamous cell carcinoma were
obtained from primary NPC patients. In addition, 24
non-cancer nasopharyngeal (NP) tissues were obtained
from patients with or without NPC. Biopsy samples con-
taining more than 70% of tumor cells [10] were selected
for further analysis. All participants (with/without NPC)
gave their informed consents before the biopsies at Jiang-
men Center Hospital, Guangdong Province and Tumor
Hospital of Hunan Province. In addition, three well-char-
acterized NPC cell lines, 5–8F with highly tumorigenic
and metastatic potential and 6–10B and CNE2 with tum-
origenic potential but disability to metastasize were col-
lected and analyzed.
Hybridization to arrays
All experiments were performed in Shenzhen Chipscreen
Biosciences Limited of China [11]. A pooling strategy was
applied; every four NPC biopsies were pooled and three
cell lines (5–8F, 6–10B and CNE2) were pooled (1:1:1).
In addition, all normal NPs were pooled together to be
used as the normal reference. Total RNA samples extracted
by Trizol reagent were further purified using Qiagen RNe-
asy mini kit (Qiagen, Inc.). 20 μg of total RNA samples
isolated respectively from each NPC pool and correspond-
ing normal reference were labeled by Cy5-dCTP and Cy3-
dCTP respectively in the presence of 2 μg oligo(dT)18
primer in a reverse transcription reaction. The resulting
labeling reactions were treated with 2 μl of 0.5 M NaOH
hydrolyzing RNA for 15 mins at room temperature, and
then neutralized with 2 μl of 0.5 M HCl. The labeled first-
strand products were purified by QIAquick PCR purifica-
tion kit and dried by speedvac. Finally, the balanced mix-
ture of Cy5- and Cy3-labeled targets was co-hybridized
against the 8K Human cDNA microarrays (CSC-GE) from
Shenzhen Chipscreen Biosciences Limited, in a humidi-
fied chamber in 30 μl of hybridization solution (7.5 μl of
4 × hybridization buffer solution, 15 μl of 50% forma-
mide and 7.5 μl of purified water) at 42°C overnight after
denaturized at 95°C for 5 minutes. Slides were washed
twice for 20 min each time in 0.1% SSC at 55°C., dried,
and scanned with a Generation III array scanner (Amer-
sham Pharmacia). The scanned images were converted to
digital data by Arrayvision 6.0.
Statistical analysis and bioinformatics analysis
Statistical identification of candidate NPC biomarkers was
based on BRB Array tool version 3.6[12]; the raw data
were first filtered to exclude uninformative spots using the
following filtering parameters: 1) minimum intensity wasJournal of Translational Medicine 2008, 6:32 http://www.translational-medicine.com/content/6/1/32
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set 200 in both fluorescence channels; 2) the lowess
smother correction method with median over entire array
was used for normalization; 3) More than 60% of expres-
sion data should have at least a 2-fold change in either
direction from gene's median value; 4) Percent of data
missing or filtered out could not exceed 50%. Class com-
parison between groups of arrays was performed by
paired samples (NPC and NP from same array) with a uni-
variate significance threshold set at a p2-value < 0.005.
To computationally analyze KEGG pathways based on
differential gene expression data, Principal Component
Analysis was performed by using BRB array tool. Gene set
expression comparisons were performed at a nominal
0.005 level of the Hotelling T-square test. P-values of the
univariate test were calculated, followed by 1000 multi-
variate permutations test. Significant pathways that have
more genes differentially expressed between NPC and NP
classes than expected by chance were selected [13].
Genes differentially expressed by NPC compared to NP
samples were evaluated for functional annotations
according to the Microarray literature-based annota-
tion(MILANO)[14,15]. This program performed auto-
matic searches in Pubmed collection for articles
containing co-occurrences of search terms. A list of genes
was used by pasting differentially expressed genes in the
"Primary Search Term" field; "oncogene, proto-oncogene,
tumor suppressor gene and nasopharyngeal carcinoma"
search terms where targeted within the "Secondary Search
Term" field. The output was a table containing the
number of hits within the Pubmed literatures for each pair
of search terms.
Semiquantitative RT-PCR and Immunohistochemistry
Purified total RNA was treated with RNase-free DNase I
(TaKaRa). After removal of the DNase I, cDNA was
reversely transcribed from 1 μg of total RNA using
oligo(dT)18 in 20 μl reaction volume. Five randomly
selected genes (PDGFRA, BIRC5, CTGF, EBI2, and
TGFBR2) differentially expressed in NPC samples com-
pared with NP samples according to our microarray data
and an invariant housekeeping gene control, ACTG1
(actin, gamma 1), were amplified from 5% of synthesized
cDNA according to the designed primers. The primer pair
designed for each gene spanned at least an intron to dis-
tinguish possibly amplified cDNA products from genomic
DNA. Subsequently, 5 μl of each PCR reaction product
was analyzed on 1.5% agarose gel from which the inten-
sity of each band was quantitated by the Vilber gel docu-
mentation system (Vilber Limited). The RT-PCR signal
from each gene was normalized by the ACTG1 gene.
Paraffin sections (4 μm) available from NPC and NP sam-
ples were deparaffinized in 100% xylene and re-hydrated
in descending ethanol series according to standard proto-
cols. Microwave-induced epitope retrieval was performed
in 10 mM citrate buffer at 95°C for 15 min. Endogenous
peroxidase activity and non-specific antigen were blocked
with peroxidase blocking reagent containing 3% hydro-
gen peroxide and serum followed by incubation with rab-
bit anti- BIRC5, CTGF and TGFBR2 protein antibody
(1:100, Boshide Company, China) at 4°C overnight. After
washing, the sections incubated using biotin-goat anti-
mouse/rabbit at room temperature for 10 minutes, were
then conjugated with horseradish peroxidase (Maixin
Company, China). The peroxidase reaction was devel-
oped with 3, 3-diaminobenzidine chromogen solution in
DAB buffer substrate. Sections were counterstained with
hematoxylin, mounted in neutral gum and analyzed
using a bright field microscope. The results were finally
analyzed by Mann-Whitney test of SPSS11.5 software.
Results
NPC samples screening
One-hundred-and-two primary NPC samples were
screened to ascertain the validity of the diagnosis based on
frozen sections. Among them, 32 samples containing
more than 70% of cancer cells [10] were qualified for fur-
ther analysis. All samples included were diagnosed as
poorly differentiated NPC.
Differentially expressed genes by NPC compare with the 
normal tissue
All 32 qualified NPC samples were pooled into 8 pools (n
= 32/4) ranging from T1 to T8 which were then co-hybrid-
ized with NP (pooled normal reference). In parallel, three
NPC cell lines were pooled as T9 and co-hybridized with
the NP reference as well. A Total of 692 genes were identi-
fied to be differentially expressed. Among them, 435
genes were shown to be up-regulated and 257 genes
down-regulated in NPC (Table 1 and Figure 1). The top 70
up-regulated and down-regulated genes are shown in
Table 2 and Table 3 respectively.
Proposed biomarkers and known oncogenes/tumor 
suppression genes for NPC
In 2006, we proposed common cancer biomarkers
expressed in cancers of various histology (melanoma,
colon, ovarian, and esophageal carcinoma) but not in
normal tissues. The analysis included training and a pre-
diction set and only genes highly significantly specific for
the cancerous tissues were proposed as biomarker candi-
dates. 16 genes were proposed as common cancer biomar-
kers based on 20 cDNA clones (cutoff P < 1.7 × 10-16),
showing a prediction accuracy of approximately 90%
[16]. To verify whether the previous results were predic-
tive also for NPC, a comparison was made between the
two studies; 6 genes (CYC1, MIF, LAMB3, TSTA3, TUBB2,
and UBE2C) of the 16 genes proposed by the previousJournal of Translational Medicine 2008, 6:32 http://www.translational-medicine.com/content/6/1/32
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study were consistently highly expressed in NPC as well.
The seventh, TRAP1, was also included among the first 50
genes in the previous study (Table 4). In addition, CyC1,
MIF, and LAMB3 appeared among the top 70 up-regu-
lated genes in NPC (Table 2).
MILANO analysis utilizes archived literature as a database
linking gene name with reported biological functions. To
detect whether these 692 differentially expressed genes
were known to be associated with NPC oncogenesis and
tumor progression, the following key words: oncogene,
Table 1: Differentially expressed genes between NPC and NP
Differential expression Number of genes Fold difference (NPC/NP)
Up-regulated 435 2.8–70.3
Down-regulated 257 0.01–0.46
Total 692
Number of genes significant at 0.005 level of the univariate test: 692
Global test: probability of getting at least 692 genes significant by chance (at the 0.005 level) if there are no real differences between the classes: 
0.00391
Class comparison and hierarchical clustering analysis Figure 1
Class comparison and hierarchical clustering analysis. T1-T8: Pooled NPCs compared to pooled NPs; T9: Pooled NPC 
cells compared to pooled NPs; Green region: down-regulated genes, Red region: up-regulated genes.Journal of Translational Medicine 2008, 6:32 http://www.translational-medicine.com/content/6/1/32
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Table 2: Top 70 up-regulated genes
No. Gene symbol False discovery rate Fold difference Description
1 SCAM-1 < 1e-07 22.68 vinexin beta (SH3-containing adaptor molecule-1)
2 SNTB1 < 1e-07 22.04 syntrophin, beta 1 (dystrophin-associated protein A1, 59 kDa, basic component 1)
3 DMWD < 1e-07 21.75 dystrophia myotonica-containing WD repeat motif
4 NPFF < 1e-07 20.72 neuropeptide FF-amide peptide precursor
5 FXYD3 < 1e-07 6.97 FXYD domain containing ion transport regulator 3
6 ATP6V0B < 1e-07 5.77 ATPase, H+ transporting, lysosomal 21 kDa, V0 subunit c"
7 PPIB < 1e-07 4.64 peptidylprolyl isomerase B (cyclophilin B)
8 HIST1H4C < 1e-07 3.81 histone 1, H4c
9 PHB 9.40e-06 7.07 prohibitin
10 NME1 9.40e-06 5.00 non-metastatic cells 1, protein (NM23A) expressed in
11 NDUFA9 9.40e-06 3.34 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39 kDa
12 BUB1B 1.20e-05 2.77 BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)
13 GRK5 1.34e-05 21.03 G protein-coupled receptor kinase 5
14 TPI1 1.34e-05 10.82 triosephosphate isomerase 1
15 CYC1 * 1.34e-05 10.36 cytochrome c-1
16 GPC5 1.55e-05 19.28 glypican 5
17 BYSL 1.67e-05 41.59 bystin-like
18 COX5B 1.67e-05 12.52 cytochrome c oxidase subunit Vb
19 KATNB1 1.84e-05 18.37 katanin p80 (WD repeat containing) subunit B 1
20 PRKAB2 2.03e-05 14.24 protein kinase, AMP-activated, beta 2 non-catalytic subunit
21 PSMB3 2.03e-05 7.43 proteasome (prosome, macropain) subunit, beta type, 3
22 PET112L 2.16e-05 21.46 PET112-like (yeast)
23 PSMD8 2.16e-05 4.88 proteasome (prosome, macropain) 26S subunit, non-ATPase, 8
24 CSF1 2.25e-05 20.35 colony stimulating factor 1 (macrophage)
25 SFTPA2 2.25e-05 17.66 surfactant, pulmonary-associated protein A2
26 PTCD1 2.25e-05 7.36 pentatricopeptide repeat domain 1
27 AARS 2.25e-05 6.65 alanyl-tRNA synthetase
28 GUK1 2.58e-05 5.61 guanylate kinase 1
29 RPS5 2.58e-05 4.66 ribosomal protein S5
30 MTL5 3.3e-05 14.60 metallothionein-like 5, testis-specific (tesmin)
31 MIF * 3.8e-05 10.72 macrophage migration inhibitory factor (glycosylation-inhibiting factor)
32 POLR2H 3.94e-05 4.68 polymerase (RNA) II (DNA directed) polypeptide H
33 IFITM2 4.38e-05 4.17 interferon induced transmembrane protein 2 (1–8D)
34 MUTYH 4.41e-05 19.61 mutY homolog (E. coli)
35 ITPKA 4.41e-05 15.19 inositol 1,4,5-trisphosphate 3-kinase A
36 FDPS 5.36e-05 3.45 farnesyl diphosphate synthase
37 HIST1H2BG 6.08e-05 10.23 histone 1, H2bg
38 INPP5D 6.15e-05 17.02 inositol polyphosphate-5-phosphatase, 145 kDa
39 IDH3G 6.47e-05 47.05 isocitrate dehydrogenase 3 (NAD+) gamma
40 ERF 6.49e-05 15.57 Ets2 repressor factor
41 PTPRJ 6.54e-05 13.86 protein tyrosine phosphatase, receptor type, J
42 ATP5G1 7.90e-05 4.82 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c, isoform 1
43 CDC45L 8.49e-05 22.94 CDC45 cell division cycle 45-like (S. cerevisiae)
44 ENO1 9.67e-05 4.75 enolase 1, (alpha)
45 IDH3B 0.0001064 3.81 isocitrate dehydrogenase 3 (NAD+) beta
46 ST3GAL4 0.0001140 28.99 ST3 beta-galactoside alpha-2,3-sialyltransferase 4
47 DDR2 0.0001152 15.87 discoidin domain receptor family, member 2
48 IFI30 0.0001188 3.88 interferon, gamma-inducible protein 30
49 EIF4G1 0.0001282 3.31 eukaryotic translation initiation factor 4 gamma, 1
50 CXorf27 0.0001372 11.62 chromosome X open reading frame 27
51 EPB41 0.0001423 4.05 erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked)
52 RPS15 0.0001427 6.91 ribosomal protein S15
53 ABCA3 0.0001432 30.18 ATP-binding cassette, sub-family A (ABC1), member 3
54 CGA 0.0001508 12.31 glycoprotein hormones, alpha polypeptide
55 SLC37A4 0.0001527 23.08 solute carrier family 37 (glycerol-6-phosphate transporter), member 4
56 NDUFB8 0.0001527 3.56 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 19 kDa
57 CSPG4 0.0001583 60.14 chondroitin sulfate proteoglycan 4 (melanoma-associated)
58 MTHFD1 0.0001583 21.57 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1,
59 CYP3A5 0.0001586 17.90 cytochrome P450, family 3, subfamily A, polypeptide 5
60 FKBP4 0.0001611 6.51 FK506 binding protein 4, 59 kDa
61 SCO2 0.0001760 14.31 SCO cytochrome oxidase deficient homolog 2 (yeast)
62 DPM2 0.0001846 12.99 dolichyl-phosphate mannosyltransferase polypeptide 2, regulatory subunit
63 NRGN 0.0001945 16.26 neurogranin (protein kinase C substrate, RC3)
64 TUBA2 0.0001988 8.87 tubulin, alpha 2
65 GAPD 0.0001990 4.99 glyceraldehyde-3-phosphate dehydrogenase
66 CDK4 0.0002205 6.73 cyclin-dependent kinase 4
67 BIRC5 0.0002380 6.62 baculoviral IAP repeat-containing 5 (survivin)
68 LAMB3 * 0.0002380 5.33 laminin, beta 3
69 SSR4 0.0002380 3.81 signal sequence receptor, delta (translocon-associated protein delta)
70 PIK4CA 0.0002398 12.01 phosphatidylinositol 4-kinase, catalytic, alpha polypeptide
* Genes appeared in table 4Journal of Translational Medicine 2008, 6:32 http://www.translational-medicine.com/content/6/1/32
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Table 3: Top 70 down-regulated genes
No. Gene symbol False discovery rate Fold difference Description
1 HERC3 < 1e-07 0.10 hect domain and RLD 3
2 PDCD4 < 1e-07 0.10 programmed cell death 4 (neoplastic transformation inhibitor)
3 SFRS5 < 1e-07 0.11 splicing factor, arginine/serine-rich 5
4 ST6GAL1 < 1e-07 0.13 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1
5 DXYS155E < 1e-07 0.16 DNA segment on chromosome X and Y (unique) 155 expressed sequence
6 KIAA1641 < 1e-07 0.17 KIAA1641
7 LEPROTL1 < 1e-07 0.17 leptin receptor overlapping transcript-like 1
8 ELL2 < 1e-07 0.23 elongation factor, RNA polymerase II, 2
9 FUSIP1 < 1e-07 0.24 FUS interacting protein (serine-arginine rich) 1
10 OGT < 1e-07 0.24 O-linked N-acetylglucosamine (GlcNAc) transferase
11 MYST4 < 1e-07 0.26 MYST histone acetyltransferase (monocytic leukemia) 4
12 RUVBL2 0.0000063 0.13 RuvB-like 2 (E. coli)
13 ARF6 0.0000063 0.13 ADP-ribosylation factor 6
14 ACTR2 0.0000063 0.14 ARP2 actin-related protein 2 homolog (yeast)
15 TRIM23 0.0000063 0.15 tripartite motif-containing 23
16 HDAC3 0.0000063 0.15 histone deacetylase 3
17 PRKAR1A 0.0000063 0.17 protein kinase, cAMP-dependent, regulatory, type I, alpha
18 DR1 0.0000063 0.18 down-regulator of transcription 1, TBP-binding (negative cofactor 2)
19 MAP4K3 0.0000063 0.21 mitogen-activated protein kinase kinase kinase kinase 3
20 PPP1CB 0.0000063 0.21 protein phosphatase 1, catalytic subunit, beta isoform
21 SEL1L 0.0000063 0.24 sel-1 suppressor of lin-12-like (C. elegans)
22 RAD17 0.0000063 0.24 RAD17 homolog (S. pombe)
23 ABI1 0.0000063 0.27 abl-interactor 1
24 ATM 0.0000063 0.27 ataxia telangiectasia mutated (includes complementation groups A, C and D)
25 STK17A 0.0000063 0.28 serine/threonine kinase 17a (apoptosis-inducing)
26 PRR4 0.0000094 0.02 proline rich 4 (lacrimal)
27 CHL1 0.0000094 0.06 cell adhesion molecule with homology to L1CAM (close homolog of L1)
28 PRKACB 0.0000094 0.10 protein kinase, cAMP-dependent, catalytic, beta
29 ELF1 0.0000094 0.13 E74-like factor 1 (ets domain transcription factor)
30 EPS15 0.0000094 0.16 epidermal growth factor receptor pathway substrate 15
31 NKTR 0.0000094 0.20 natural killer-tumor recognition sequence
32 DNAJC10 0.0000094 0.21 DnaJ (Hsp40) homolog, subfamily C, member 10
33 RARB 0.0000094 0.25 retinoic acid receptor, beta
34 FBXO9 0.0000094 0.29 F-box protein 9
35 MSMBROCK1 0.0000120 0.13 microseminoprotein, beta-
36 TADA3L 0.0000120 0.14 Rho-associated, coiled-coil containing protein kinase 1
37 TNFAIP8 0.0000120 0.16 transcriptional adaptor 3 (NGG1 homolog, yeast)-like
38 TGFBR2 0.0000120 0.16 tumor necrosis factor, alpha-induced protein 8
39 SLC23A1 0.0000120 0.19 transforming growth factor, beta receptor II (70/80 kDa)
40 FOXO1A 0.0000120 0.20 solute carrier family 23 (nucleobase transporters), member 1
41 USP12 0.0000120 0.20 forkhead box O1A (rhabdomyosarcoma)
42 CD2AP 0.0000134 0.18 ubiquitin specific protease 12
43 UBE4A 0.0000134 0.18 CD2-associated protein
44 SCP2 0.0000134 0.21 ubiquitination factor E4A (UFD2 homolog, yeast)
45 CAPN7 0.0000134 0.23 sterol carrier protein 2
46 PTPRS 0.0000134 0.24 calpain 7
47 BCL6 0.0000134 0.25 protein tyrosine phosphatase, receptor type, S
48 AGA 0.0000134 0.32 B-cell CLL/lymphoma 6 (zinc finger protein 51)
49 PROS1 0.0000134 0.33 aspartylglucosaminidase
50 UBL3 0.0000155 0.06 protein S (alpha)
51 BRF1 0.0000155 0.12 ubiquitin-like 3
52 ANP32B 0.0000155 0.15 BRF1 homolog, subunit of RNA polymerase III transcription initiation factor IIIB
53 AMY2B 0.0000155 0.25 acidic (leucine-rich) nuclear phosphoprotein 32 family, member B
54 FUBP3 0.0000167 0.07 amylase, alpha 2B; pancreatic
55 MAN2A1 0.0000167 0.15 far upstream element (FUSE) binding protein 3
56 TERF2IP 0.0000167 0.21 mannosidase, alpha, class 2A, member 1
57 PRKRIR 0.0000167 0.24 telomeric repeat binding factor 2, interacting protein
58 HRB2 0.0000167 0.27 protein-kinase, interferon-inducible double stranded RNA dependent inhibitor, repressor of 
(P58 repressor)
59 MAP4K5 0.0000167 0.28 HIV-1 rev binding protein 2
60 PPM1B 0.0000184 0.16 mitogen-activated protein kinase kinase kinase kinase 5
61 PSIP1 0.0000184 0.16 protein phosphatase 1B (formerly 2C), magnesium-dependent, beta isoform
62 TMEM1 0.0000184 0.18 PC4 and SFRS1 interacting protein 1
63 CDK5R1 0.0000184 0.31 transmembrane protein 1
64 ZA20D2 0.0000203 0.27 cyclin-dependent kinase 5, regulatory subunit 1 (p35)
65 AIM2 0.0000216 0.14 zinc finger, A20 domain containing 2
66 NBR1 0.0000216 0.19 absent in melanoma 2
67 TCN1 0.0000216 0.26 neighbor of BRCA1 gene 1
68 STXBP3 0.0000225 0.20 transcobalamin I (vitamin B12 binding protein, R binder family)
69 ZNF265 0.0000225 0.20 syntaxin binding protein 3
70 HERC3 0.0000240 0.24 zinc finger protein 265Journal of Translational Medicine 2008, 6:32 http://www.translational-medicine.com/content/6/1/32
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proto-oncogene, tumor suppressor and nasopharyngeal
carcinoma were applied as input in the MILANO searcher
engine. In this way, we could screen for known and candi-
date oncogenes or tumor suppressor genes reported in
other human malignancies or in NPC. Table 5 presents 10
genes (4 up-regulated and 6 down-regulated in NPC) with
known oncogenic or tumor suppressor function in vari-
ous human malignancies. Some genes, such as MIF and
CCDN2, bore predominant pro-tumor progression func-
tions, other genes, such as KLF5 and TGFBR2, contribute
to tumor suppression functions. Notably, the results from
MILANO analysis were consistent with our microarray
data; the differential expression of the genes proposed as
oncogene or Proto-oncogene by MILANO consisted of
genes with >5-fold difference (our microarray data), rang-
ing from 6.62 to 20.15. Conversely, the fold difference of
genes associated with tumor suppressor function by
MILANO was less than 0.5, ranging from 0.14 to 0.27.
Computational pathway analysis
The pathway analysis was done using the gene set expres-
sion comparison kit [11] implemented in BRB-Array-
Tools. The human pathway lists determined by KEGG
Pathways Database was selected. Significance threshold of
Hotelling's T-square test was set at 0.005 using the first
three principal components. Significant pathways were
listed in Table 6. Among them, several pathways were
involved in cell growth and death, important signal trans-
duction and immune system. Interestingly, several path-
ways associated with immune function are involved
(Table 6 and 7) with the overexpression of interleukin-1β
and interleukin-6.
Validation of differential regulated genes by Semi-
quantitative RT-PCR and Immunohistochemistry
To validate the microarray data, differential gene expres-
sion was confirmed by Semi-quantitative RT-PCR in 5
genes randomly selected from the 692 differentially
expressed genes. These genes displayed similar expression
patterns (Figure 2) to the microarray data; ratio of expres-
sion in NPC/NP was 0.32 in CTGF, 0.24 in TGFBR2, 0.36
in PDGFRA, 0.46 in EBI2, 2.67 in BIRC5, which was con-
cordant with array data.
To further evaluate the reliability of the microarray data,
three genes, selected as representatives were analyzed by
Immunohistochemistry. According to our array analysis,
BIRC5 was up-regulated and both of TGFBR2 and
Table 5: MILANO analysis for oncogenes and tumor suppressor genes
Gene symbol Role1 Fold difference2 (NPC/NP) Description Map Location
MIF Candidate oncogene 10.72 macrophage migration inhibitory factor (glycosylation-
inhibiting factor)
22q11.23
BIRC5 Oncogene 6.62 baculoviral IAP repeat-containing 5 (survivin) 17q25
PTTG1 Proto-oncogene 7.35 pituitary tumor-transforming 1 5q35.1
CCND2 Proto-oncogene 20.15 cyclin D2 12p13
ATM Tumor suppressor 0.27 ataxia telangiectasia mutated (includes 
complementation groups A, C and D)
11q22-q23
FOXO1A Tumor suppressor 0.20 forkhead box O1A (rhabdomyosarcoma) 13q14.1
TGFBR2 Tumor suppressor 0.19 transforming growth factor, beta receptor II 3p22
PRKAR1A Tumor suppressor 0.17 protein kinase, cAMP-dependent, regulatory, type I, 
alpha
17q23-q24
KLF5 Tumor suppressor 0.17 Kruppel-like factor 5 (intestinal) 13q22.1
PDCD4 Tumor suppressor 0.10 programmed cell death 4 (neoplastic transformation 
inhibitor)
10q24
1 Role: functions identified by MILANO
2 Fold difference: extracted from our microarray data.
Table 4: Proposed NPC biomarkers according to our previous study (Basil et al [14])
Gene symbol Fold difference (NPC/NP) Parametric p-value False discovery rate Description
CYC1 * 10.36 4.00E-07 1.34E-05 Cytochrome c-1
MIF * 10.72 2.10E-06 3.83E-05 Macrophage migration inhibitory factor
LAMB3 * 5.33 2.43E-05 0.000238 Laminin, beta 3
TSTA3 27.22 9.77E-05 0.0007454 Tissue specific transplantation antigen P35B
TUBB2 43.51 0.0001256 0.0009051 Tubulin, beta 2
UBE2C 20.29 0.0009964 0.0045488 Ubiquitin-conjugating enzyme E2C
TRAP1 10.94 0.0026581 0.0097038 TNF receptor-associated protein 1
* The genes were in top 70 up-regulated genes of table 2Journal of Translational Medicine 2008, 6:32 http://www.translational-medicine.com/content/6/1/32
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CTGF(Figure 3) were down-regulated in NPC. The protein
expression of these three genes was observed in totally 55
NPC samples and 46 NP samples. The Mann-Whitney test
of positive rates in NPC and NP samples indicated that
BIRC5 protein expression was significantly higher in NPC
(P < 0.004) compared to NP samples, while TGFBR2 and
CTGF were significantly lower in NPC (P < 0.002 and
0.001 respectively) compared to NP samples, supporting
the reliability of the array data.
Discussion
Nasopharyngeal carcinoma is a special type of squamous
cell carcinoma of head and neck associated with EBV
infection, environmental factors and genetic aberrance.
Clinically, poorly differentiated squamous cell carcinoma
may account for 98% NPC patients while well differenti-
ated squamous cell carcinoma and adenocarcinoma are
rarely encountered in Southern China where this disease
is particularly prevalent. The present study focused on
alteration of gene expression in poorly differentiated
squamous cell carcinoma of the nasopharynx. Owing to
anatomical limitations, NPC and NP specimens collected
from the clinic are usually very scarce and, because in
most cases biopsies are semi-blindly performed through a
forceps rather than a scalpel, it, is hard to accurately
exclude normal NP tissue contamination from cancerous
ones. Even in NPC biopsies without normal NP cells, the
content of NPC cell appears to vary greatly. Therefore,
Table 6: Significant pathways at the nominal 0.005 level of the Hotelling T-square test *
Related Function Kegg Pathway Pathway description Number of genes p-value
Cell Growth & Death hsa04210 Apoptosis 9 1.20E-06
hsa04110 Cell cycle 10 2.10E-06
Signal Transduction hsa04020 Calcium signaling pathway 13 1.80E-06
hsa04010 MAPK signaling pathway 19 1.11E-05
hsa04310 Wnt signaling pathway 10 1.24E-05
hsa04630 Jak-STAT signaling pathway 7 3.64E-05
hsa04070 Phosphatidylinositol signaling system 7 8.03E-05
hsa04370 VEGF signaling pathway 5 0.000333
Immune System hsa04650 Natural killer cell mediated cytotoxicity 7 1.67E-05
hsa04640 Hematopoietic cell lineage 6 2.63E-05
hsa04662 B cell receptor signaling pathway 9 5.01E-05
hsa04660 T cell receptor signaling pathway 6 5.06E-05
hsa04664 Fc epsilon RI signaling pathway 7 9.76E-05
hsa04610 Complement and coagulation cascades 5 0.0001297
hsa04620 Toll-like receptor signaling pathway 5 0.003536
Signaling Molecules and Interaction hsa04080 Neuroactive ligand-receptor interaction 12 1.00E-07
hsa04060 Cytokine-cytokine receptor interaction 15 3.00E-07
hsa04514 Cell adhesion molecules (CAMs) 9 1.50E-05
hsa04512 ECM-receptor interaction 8 0.0004294
Endocrine System hsa04910 Insulin signaling pathway 8 6.00E-06
hsa04920 Adipocytokine signaling pathway 5 6.90E-06
hsa03320 PPAR signaling pathway 6 3.42E-05
hsa04912 GnRH signaling pathway 8 3.66E-05
Cell Communication hsa04510 Focal adhesion 17 9.20E-06
hsa04520 Adherens junction 5 2.95E-05
hsa04540 Gap junction 10 3.89E-05
hsa04530 Tight junction 10 4.48E-05
Others hsa04810 Regulation of actin cytoskeleton 11 3.90E-06
hsa00260 Glycine, serine and threonine metabolism 6 1.54E-05
hsa00190 Oxidative phosphorylation 17 3.14E-05
hsa00230 Purine metabolism 18 3.22E-05
hsa00500 Starch and sucrose metabolism 9 7.68E-05
hsa00980 Metabolism of xenobiotics by cytochrome P450 7 8.06E-05
hsa00240 Pyrimidine metabolism 12 0.0001352
hsa04730 Long-term depression 6 0.0002265
hsa04720 Long-term potentiation 7 0.0003216
hsa04360 Axon guidance 11 0.0007991
* Significance threshold of permutation tests: 0.005
Significance threshold of Hotelling's T-square tests: 0.005
Number of principal components for Hotelling's T-square tests: 3
Square tests: 3Journal of Translational Medicine 2008, 6:32 http://www.translational-medicine.com/content/6/1/32
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Table 7: List of genes involving in Immune function
Pathway Description Gene symbol Parametric 
p-value
Fold Difference 
(NPC/NP)
protein kinase C, beta 1 PRKCB1 2.20E-05 0.14
integrin, beta 2 (antigen CD18 (p95), lymphocyte function-
associated antigen 1; macrophage antigen 1 (mac-1) beta 
subunit)
ITGB2 0.0001733 0.18
Natural killer cell mediated nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 1
NFATC1 0.0004205 0.23
cytotoxicity phosphoinositide-3-kinase, catalytic, gamma polypeptide PIK3CG 0.0002216 0.24
vav 2 oncogene VAV2 0.0024579 7.77
TYRO protein tyrosine kinase binding protein TYROBP 0.0005303 14.39
tumor necrosis factor receptor superfamily, member 10b TNFRSF10B 0.0006507 14.91
complement component (3d/Epstein Barr virus) receptor 2 CR2 0.0001842 0.02
interleukin 1, beta IL1B 0.0043926 8.27
Hematopoietic cell lineage interleukin 6 (interferon, beta 2) IL6 0.0024281 8.29
integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) ITGB3 0.0008031 10.39
CD14 antigen CD14 4.15E-05 16.88
colony stimulating factor 1 (macrophage) CSF1 1.00E-06 20.35
complement component (3d/Epstein Barr virus) receptor 2 CR2 0.0001842 0.02
protein kinase C, beta 1 PRKCB1 2.20E-05 0.14
B cell receptor Bruton agammaglobulinemia tyrosine kinase BTK 5.39E-05 0.17
signaling pathway nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 1
NFATC1 0.0004205 0.23
phosphoinositide-3-kinase, catalytic, gamma polypeptide PIK3CG 0.0002216 0.24
nuclear factor of kappa light polypeptide gene enhancer in B-
cells 2
NFKB2 0.0019236 7.57
vav 2 oncogene VAV2 0.0024579 7.77
glycogen synthase kinase 3 beta GSK3B 0.0021047 13.20
inositol polyphosphate-5-phosphatase, 145kDa INPP5D 4.10E-06 17.02
nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 1
NFATC1 0.0004205 0.23
phosphoinositide-3-kinase, catalytic, gamma polypeptide PIK3CG 0.0002216 0.24
T cell receptor cyclin-dependent kinase 4 CDK4 2.20E-05 6.73
signaling pathway nuclear factor of kappa light polypeptide gene enhancer in B-
cells 2
NFKB2 0.0019236 7.57
vav 2 oncogene VAV2 0.0024579 7.77
mitogen-activated protein kinase kinase kinase 14 MAP3K14 0.0008295 11.17
membrane-spanning 4-domains, subfamily A, member 2 (Fc 
fragment of IgE, high affinity I, receptor for; beta 
polypeptide)
MS4A2 6.30E-06 0.04
Fc epsilon RI signaling 
pathway
protein kinase C, beta 1 PRKCB1 2.20E-05 0.14
Bruton agammaglobulinemia tyrosine kinase BTK 5.39E-05 0.17
phosphoinositide-3-kinase, catalytic, gamma polypeptide PIK3CG 0.0002216 0.24
phospholipase A2, group V PLA2G5 0.0017931 6.86
vav 2 oncogene VAV2 0.0024579 7.77
inositol polyphosphate-5-phosphatase, 145kDa INPP5D 4.10E-06 17.02
complement component 3 C3 2.25E-05 0.01
Complement and 
coagulation
complement component (3d/Epstein Barr virus) receptor 2 CR2 0.0001842 0.02
cascades protein S (alpha) PROS1 5.00E-07 0.06
coagulation factor XIII, A1 polypeptide F13A1 0.0002893 0.22
complement factor H CFH 0.0018395 0.26
phosphoinositide-3-kinase, catalytic, gamma polypeptide PIK3CG 0.0002216 0.24
Toll-like receptor signaling 
pathway
nuclear factor of kappa light polypeptide gene enhancer in B-
cells 2
NFKB2 0.0019236 7.57
interleukin 1, beta IL1B 0.0043926 8.27
interleukin 6 (interferon, beta 2) IL6 0.0024281 8.29
CD14 antigen CD14 4.15E-05 16.88Journal of Translational Medicine 2008, 6:32 http://www.translational-medicine.com/content/6/1/32
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screening the specimens obtained from the clinic for pres-
ence of a sufficient number of cancer cells was the critical
step in order to assure the uniformity and validity of the
microarray results. We found that tumor cell content var-
ied from 5% to 95% in 102 pathologically diagnosed pri-
mary NPC samples among which only 32 samples
contained more than 70% of cancer cells; the latter were
qualified for further analysis.
In the present study, we applied the cDNA microarray
technology to study differential gene expression between
NPC and NP samples from Southern China. A pooling
strategy was used to improve the statistical power and
reduce individual heterogeneity. Class comparison analy-
sis revealed 692 deferentially expressed genes with 2-fold
or greater difference at a significance p-value of < 0.005.
Of these genes, 435 were up-regulated and 257 were
down-regulated. Subsequently, all the differentially
expressed genes were further screened by MILANO analy-
sis. After excluding the genes without association with
limited oncogene and tumor suppressor terms when
searching in MILANO, 10 genes were found to be reported
consistently as known oncogenes and tumor suppressor
genes in various human malignancies in previous studies.
4 genes were up-regulated and 6 genes down-regulated.
Interestedly, of these 10 genes, three genes (MIF, BIRC5
and ATM) have been documented in NPC associated arti-
cles, and the rest genes (PTTG1, FOXO1A, TGFBR2,
PRKAR1A, CCND2, KLF5, and PDCD4) have never
reported or poorly understood in NPC before.
It is well known that oncogenes tend to be up-regulated
and tumor suppressor genes are down-regulated in malig-
nant condition. Based on CGH, chromosomal abnormal-
ities associated with primary and metastatic NPC have
been identified in all human chromosomes except chro-
mosome Y [3,4,7,17-20]. BIRC5 up-regulated in NPC
(oncogenes) was located on 17q21.3-25. As down-regu-
lated tumor suppressors in NPC, FOXO1A and KLF5
existed on 13q14.1-34, ATM on 11 q13-23, and TGFBR2
on 3p21.3-24. The expression level of these genes was
consistent with corresponding chromosomal gains or
losses. However, the gene expression of the rest of the
genes did not correspond with their chromosomal status.
MIF and PTTG1 up-regulated in NPC (oncogenes) were
on 19p13.3 and 5q35.1 respectively and PRKAR1A and
PDCD4 down-regulated in NPC (tumor suppressors)
were mapped to chromosome 17q22-q24 and 10q24
respectively, but no corresponding high frequency of
chromosomal alterations in those region have been
reported in association with NPC. Down-regulation of
some genes might be involved in other mechanisms
including promoter hypermethylation or additional mod-
ification, promoter mutation and gene mutation.
Several studies have shown that several differentially
expressed genes identified in this study have functions
Immunohistochemistry detection of three proteins in NPC  and NP (×200) Figure 3
Immunohistochemistry detection of three proteins 
in NPC and NP (×200). A: BIRC5 in NPC (strong posi-
tive); B: BIRC5 in NP (weak positive); C: CTGF in NP (strong 
positive); D: CTGF in NPC (weak positive); E: TGFBR2 in NP 
(strong positive); F: TGFBR2 in NPC (weak positive).
Histogram identification of differentially expressed genes  using semi-quantitative RT-PCR (average ratio) Figure 2
Histogram identification of differentially expressed genes 
using semi-quantitative RT-PCR (average ratio).
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associated with cell proliferation, cell apoptosis, cell cycle,
angiogenesis and signal transducer activity, creating an
active proliferation and progression status at tumor site.
As an up-regulated oncogene, MIF, a macrophage migra-
tion inhibitory factor, may function as an autocrine medi-
ator of both growth factor- and integrin-dependent
sustained ERK MAPK activation, cyclin D1 expression,
and cell cycle progression. Swant[19]http://
linus.nci.nih.gov/BRB-ArrayTools.html found that MIF
could stimulate cyclin D1 by recruiting Rho GTPase and
its downstream signaling for MAPK activation. EBV onco-
gene LMP1 in NPC, PTGS2 in endometrial carcinoma[21]
and MYC in breast cancer[22] may induce the BIRC5
expression by different pathways. As a tumor suppressor,
KLF5, a transcription factor associated with cellular sign-
aling involved in cell proliferation and oncogenesis,
inhibits the expression of BIRC5 by binding p53 in acute
lymphoblastic leukemia[23], suggesting that anti-apop-
totic factor BIRC5 may play a key role in gene-regulated
network of NPC. Pituitary tumor-transforming gene-1
(PTTG1) is overexpressed in a variety of endocrine-related
tumors and nonendocrine-related cancers involving the
central nervous, pulmonary, and gastrointestinal systems.
It is a potent oncogene because of its ability to combine
with p53 and thus to prevent p53 from binding to DNA
and inducing cell death[24]. DNA damage and the conse-
quent activation of the DNA damage response (DDR)
pathway is one of the occasions for the tumor initiation
and progression. Among tumor suppressors, ATM, a
major regulator of the cellular response to DNA double-
strand breaks, may be a key factor in the DDR pathway.
Knocking down ATM with a short hairpin RNA (shRNA)
could block p53 induction in response to aberrant
STAT5A activation and bypass the senescence response to
this oncogene when the Rb pathway was also inactivated.
In addition, knocking down ATM could inhibit E2F1-
induced senescence and, in combination with Rb inactiva-
tion, suppress RasV12-induced senescence[25]. TGF-β
exerted its tumor-suppressor effects on many tumors by
binding to the transmembrane TGF-β type II receptor
(TGFBR2, a tumor suppressor), which caused the recruit-
ment of the TGF-β type I receptor (TGFBR1) with subse-
quent activation of the receptor complex. Decreased
expression of TGFBR2 found in NPC may block this
important pathway of tumor-growth inhibition and pro-
mote the NPC malignant transformation[26]. Pro-
grammed cell death-4 (PDCD4) is a new discovered
tumor suppressor protein that inhibits protein synthesis
by suppression of translation initiation. A recent study
showed that PDCD4 suppressed tumor progression in
human colon carcinoma cells by the novel mechanism of
down-regulating MAP4K1 transcription, with consequent
inhibition of c-Jun activation and AP-1-dependent tran-
scription[27]. Down-regulated expression of PDCD4 in
NPC tissue and cells suggested a negatively regulation role
in NPC pathogenesis. Tumor suppressor FOXO1A, a
FOXO transcription factor, has been implicated in several
human cancers. However, it has not been reported in NPC
to date. Shore[28] found that Expression of the EBV genes
for latent membrane protein 1 and latent membrane pro-
tein 2A could decrease Foxo1A expression by phosphati-
dylinositol 3-kinase-mediated nuclear export.
Oncoprotein P3k and Akt can suppress the FoxO1 expres-
sion by a common denominator of their pathway[29].
The tumor suppressor gene, PRKAR1A, coding for the
Type 1alpha regulatory subunit of protein kinase A, a crit-
ical cellular component of a number of cyclic nucleotide-
dependent signaling pathways, is mutated in Carney com-
plex, a familial neoplasia syndrome that is associated with
thyroid tumors[30]. Its decreased expression in NPC may
be caused by similar gene mutation, which is remained to
be further elucidated.
Interestedly, several studies really supported the dysregu-
lation of several pathways, such as Wnt signaling, MARK
signaling [31,32], NF-kB-Apoptosis resistance, integrin
signaling[32] in NPC although most of pathways involv-
ing cell growth and death, cell communication, and
immune system, etc. have not been well documented. In
our present study, our computational pathway analysis of
692 differentially expressed genes strongly supported that
multiple biological pathways were indeed involved in
NPC oncogenesis. Particularly, we found that most of
immune system associated pathways, such as Natural
killer cell mediated cytotoxicity, Hematopoietic cell line-
age, B cell receptor signaling, T cell receptor signaling, Fc
epsilon RI signaling, Complement and coagulation cas-
cades, and Toll-like receptor signaling, were involved, sug-
gesting that they may play important roles in NPC.
Recently, there has been increasing interest in identify
diagnostic tools that could complement standard his-
topathologic evaluation to determine the presence of can-
cer cells in tissues[33], a previous study from our group
applied a high throughput microarray technology to
investigate a broad range of cancer types and identified 16
proposed universal cancer biomarkers with high predic-
tion accuracy. These biomarkers could be used broadly to
improve the sensitivity and specificity of cancer staging
and early detection of loco-regional or systemic recurrence
[16]. Among the 16 common cancer biomarkers identi-
fied as highly predictive by the previous study which did
not include NPC samples, 6 genes (CYC1, MIF, LAMB3,
TSTA3, TUBB2, and UBE2C) were found to be highly
expressed in NPC by the study. The seventh gene, TRAP1,
was also included in the first 50 genes. Therefore, CYC1,
MIF, LAMB3, TSTA3, TUBB2, UBE2C, and TRAP1 may
possibly represent NPC candidate biomarkers adding a
molecular dimension to the histo-pathological diagnosis
of the disease and these biomarkers may be added to theJournal of Translational Medicine 2008, 6:32 http://www.translational-medicine.com/content/6/1/32
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pathologist's repertoire for the uncovering of NPC patho-
genesis when comprehensive histologic evaluation is not
sufficient. Obviously further validation will be needed in
the future. Moreover, NPC could share the expression of
various biomarkers with other cancers of disparate histol-
ogy suggesting the existence of common pathways of
oncogenesis that may be most relevant as therapeutic tar-
gets.
Conclusion
Using microarray technology and bioinformatics analysis,
we identified 692 differentially expressed genes. Among
these genes, 10 known oncogenes and tumor suppressors
were picked out as key genes which mainly promoted
NPC tumor genesis. Seven genes were also proposed as
NPC candidate cancer biomarkers as they were observed
universal cancer biomarkers in a previous study analyzing
tumors of different histology. Computational pathway
analysis suggested the likelihood that the multi-pathways
are involved in the oncogenesis of NPC including a
chronic inflammatory process mediated through classic
cytokine pathways.
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